# AZD6738 Plus Durvalumab in Biliary Tract Cancer

> **NCT04298008** · PHASE2 · UNKNOWN · sponsor: **Seoul National University Hospital** · enrollment: 26 (estimated)

## Conditions studied

- Bile Duct Cancer
- Chemotherapy Effect

## Interventions

- **DRUG:** AZD6738
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT04298008
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-25
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04298008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04298008, "AZD6738 Plus Durvalumab in Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04298008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*